Sichuan Baili Pharmaceutical Co., Ltd.
Shanghai, Shanghai Municipality
What changed
Phase II trial registered: A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
9mo agoTrial registeredSep 26, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 53 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase II
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
R01 · $504k · non-dilutive
Sep 5, 2024BAYLOR COLLEGE OF MEDICINE · PI JI, DAOYUN · NIMH · award ends Jul 31, 2029 · Neural circuit mechanisms in observational spatial working memory
NIH RePORTER · NIH RePORTER 11184416 (opens the source filing in a new tab)
- Trial
PHASE2 registered
Oct 20, 2023Head and Neck Squamous Cell Carcinoma · RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
ClinicalTrials.gov · NCT06006169 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources